Skip to content

Study · Systematic review · 2025

8 results

The effect of glucagon-like Peptide-1 receptor agonists on measures of suicidality: A systematic review.

Valentino K, Teopiz KM, Cheung W, Wong S, Le GH, Rosenblat JD, Mansur RB, McIntyre RS

Journal of psychiatric research6 Feb 2025Cited by 19 (Europe PMC)

PMID39956093 (opens in a new tab)DOI10.1016/j.jpsychires.2025.02.008 (opens in a new tab)PepBankPUB-39956093
Publisher pagePubMedAsk about this study
Jump to 8 results

Summary

Reports submitted to the FDA and EMA suggest that Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) may be associated with an elevated risk of suicidality. To ascertain this association across available pharmacovigilance and cohort studies, Pubmed, Medline, Cochrane Library, PsychInfo, Embase, Scopus, and Web of Science were searched from database inception to November 20, 2024 in accordance with PRISMA guidelines. A manual search using Google Scholar was also conducted to identify additional studies. Cohort studies were assessed for quality using the Newcastle-Ottawa Scale. We endeavored to define and operationalize suicidality as suicide ideation (SI), suicide attempts (SA), and suicide completion (SC), in cases where study authors failed to separate these three dimensions, the term "suicidality" was applied. 22 studies meeting inclusion criteria comprised of pharmacovigilance (n = 10) and cohort studies (n = 12) were identified. Pharmacovigilance studies indicate that semaglutide and liraglutide are associated with disproportionate reporting of SI. Results from cohort studies indicate that GLP-1 RAs are not consistently associated with an increase in any aspect of suicidality; instead, some agents are associated with decreased SI and SA. There is inadequate information to ascertain whether causality exists linking GLP-1 RAs to suicidality. Ongoing vigilance and further information is required to inform if the possibility of causality exists. Practitioners prescribing GLP-1 RAs should be vigilant for the possibility of the emergence of SI and be aware of the higher risk of mental illness in persons who would be candidates for GLP-1 RAs (e.g. Type 2 Diabetes, obesity).
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study8

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanSystematic reviewSafety outcome

    In pharmacovigilance studies, semaglutide was associated with disproportionate reporting of suicide ideation.

    In plain wordsIn safety-report studies, semaglutide was linked to disproportionate reports of suicidal thoughts.

    Peptide
    Semaglutide
    Outcome
    Direction not reportedSuicide ideation reporting
    Study

    n: not reported in source

    Outcome group
    Adverse events · Mental health and mood
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Pharmacovigilance studies indicate that semaglutide and liraglutide are associated with disproportionate reporting of SI.
    2 context sentences
    Summary · context
    To ascertain this association across available pharmacovigilance and cohort studies, Pubmed, Medline, Cochrane Library, PsychInfo, Embase, Scopus, and Web of Science were searched from database inception to November 20, 2024 in accordance with PRISMA guidelines.
    Summary · context
    22 studies meeting inclusion criteria comprised of pharmacovigilance (n = 10) and cohort studies (n = 12) were identified.
  2. 02HumanSystematic reviewSafety outcome

    In pharmacovigilance studies, liraglutide was associated with disproportionate reporting of suicide ideation.

    In plain wordsIn safety-report studies, liraglutide was linked to disproportionate reports of suicidal thoughts.

    Peptide
    Liraglutide
    Outcome
    Direction not reportedSuicide ideation reporting
    Study

    n: not reported in source

    Outcome group
    Adverse events · Mental health and mood
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Pharmacovigilance studies indicate that semaglutide and liraglutide are associated with disproportionate reporting of SI.
    2 context sentences
    Summary · context
    To ascertain this association across available pharmacovigilance and cohort studies, Pubmed, Medline, Cochrane Library, PsychInfo, Embase, Scopus, and Web of Science were searched from database inception to November 20, 2024 in accordance with PRISMA guidelines.
    Summary · context
    22 studies meeting inclusion criteria comprised of pharmacovigilance (n = 10) and cohort studies (n = 12) were identified.

Studies that did not test the peptide alone6

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

  1. 03HumanNot a test of Semaglutide aloneSystematic reviewSafety outcome

    Across GLP-1 receptor agonists, some unspecified agents in cohort studies were associated with decreased suicide ideation.

    In plain wordsIn cohort studies, some unspecified GLP-1 medicines were linked to fewer suicidal thoughts.

    Peptide
    Semaglutide
    Outcome
    DecreaseSuicide ideation
    Study

    n: not reported in source

    Outcome group
    Adverse events · Mental health and mood

    Source sentences

    Summary
    Results from cohort studies indicate that GLP-1 RAs are not consistently associated with an increase in any aspect of suicidality; instead, some agents are associated with decreased SI and SA.
    2 context sentences
    Summary · context
    To ascertain this association across available pharmacovigilance and cohort studies, Pubmed, Medline, Cochrane Library, PsychInfo, Embase, Scopus, and Web of Science were searched from database inception to November 20, 2024 in accordance with PRISMA guidelines.
    Summary · context
    22 studies meeting inclusion criteria comprised of pharmacovigilance (n = 10) and cohort studies (n = 12) were identified.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  2. 04HumanNot a test of Liraglutide aloneSystematic reviewSafety outcome

    Across GLP-1 receptor agonists, some unspecified agents in cohort studies were associated with decreased suicide ideation.

    In plain wordsIn cohort studies, some unspecified GLP-1 medicines were linked to fewer suicidal thoughts.

    Peptide
    Liraglutide
    Outcome
    DecreaseSuicide ideation
    Study

    n: not reported in source

    Outcome group
    Adverse events · Mental health and mood

    Source sentences

    Summary
    Results from cohort studies indicate that GLP-1 RAs are not consistently associated with an increase in any aspect of suicidality; instead, some agents are associated with decreased SI and SA.
    2 context sentences
    Summary · context
    To ascertain this association across available pharmacovigilance and cohort studies, Pubmed, Medline, Cochrane Library, PsychInfo, Embase, Scopus, and Web of Science were searched from database inception to November 20, 2024 in accordance with PRISMA guidelines.
    Summary · context
    22 studies meeting inclusion criteria comprised of pharmacovigilance (n = 10) and cohort studies (n = 12) were identified.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  3. 05HumanNot a test of Semaglutide aloneSystematic reviewSafety outcome

    Across GLP-1 receptor agonists, some unspecified agents in cohort studies were associated with decreased suicide attempts.

    In plain wordsIn cohort studies, some unspecified GLP-1 medicines were linked to fewer suicide attempts.

    Peptide
    Semaglutide
    Outcome
    DecreaseSuicide attempts
    Study

    n: not reported in source

    Outcome group
    Adverse events · Mental health and mood

    Source sentences

    Summary
    Results from cohort studies indicate that GLP-1 RAs are not consistently associated with an increase in any aspect of suicidality; instead, some agents are associated with decreased SI and SA.
    2 context sentences
    Summary · context
    To ascertain this association across available pharmacovigilance and cohort studies, Pubmed, Medline, Cochrane Library, PsychInfo, Embase, Scopus, and Web of Science were searched from database inception to November 20, 2024 in accordance with PRISMA guidelines.
    Summary · context
    22 studies meeting inclusion criteria comprised of pharmacovigilance (n = 10) and cohort studies (n = 12) were identified.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  4. 06HumanNot a test of Liraglutide aloneSystematic reviewSafety outcome

    Across GLP-1 receptor agonists, some unspecified agents in cohort studies were associated with decreased suicide attempts.

    In plain wordsIn cohort studies, some unspecified GLP-1 medicines were linked to fewer suicide attempts.

    Peptide
    Liraglutide
    Outcome
    DecreaseSuicide attempts
    Study

    n: not reported in source

    Outcome group
    Adverse events · Mental health and mood

    Source sentences

    Summary
    Results from cohort studies indicate that GLP-1 RAs are not consistently associated with an increase in any aspect of suicidality; instead, some agents are associated with decreased SI and SA.
    2 context sentences
    Summary · context
    To ascertain this association across available pharmacovigilance and cohort studies, Pubmed, Medline, Cochrane Library, PsychInfo, Embase, Scopus, and Web of Science were searched from database inception to November 20, 2024 in accordance with PRISMA guidelines.
    Summary · context
    22 studies meeting inclusion criteria comprised of pharmacovigilance (n = 10) and cohort studies (n = 12) were identified.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  5. 07HumanNot a test of Liraglutide aloneSystematic reviewSafety outcome

    Across GLP-1 receptor agonists including liraglutide, cohort studies were not consistently associated with increased suicidality.

    In plain wordsAcross GLP-1 medicines including liraglutide, cohort studies did not consistently link them to more suicidality.

    Peptide
    Liraglutide
    Outcome
    Direction not reportedSuicidality association
    Study

    n: not reported in source

    Outcome group
    Adverse events · Mental health and mood

    Source sentences

    Summary
    Results from cohort studies indicate that GLP-1 RAs are not consistently associated with an increase in any aspect of suicidality; instead, some agents are associated with decreased SI and SA.
    2 context sentences
    Summary · context
    To ascertain this association across available pharmacovigilance and cohort studies, Pubmed, Medline, Cochrane Library, PsychInfo, Embase, Scopus, and Web of Science were searched from database inception to November 20, 2024 in accordance with PRISMA guidelines.
    Summary · context
    22 studies meeting inclusion criteria comprised of pharmacovigilance (n = 10) and cohort studies (n = 12) were identified.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  6. 08HumanNot a test of Semaglutide aloneSystematic reviewSafety outcome

    Across GLP-1 receptor agonists including semaglutide, cohort studies were not consistently associated with increased suicidality.

    In plain wordsAcross GLP-1 medicines including semaglutide, cohort studies did not consistently link them to more suicidality.

    Peptide
    Semaglutide
    Outcome
    Direction not reportedSuicidality association
    Study

    n: not reported in source

    Outcome group
    Adverse events · Mental health and mood

    Source sentences

    Summary
    Results from cohort studies indicate that GLP-1 RAs are not consistently associated with an increase in any aspect of suicidality; instead, some agents are associated with decreased SI and SA.
    2 context sentences
    Summary · context
    To ascertain this association across available pharmacovigilance and cohort studies, Pubmed, Medline, Cochrane Library, PsychInfo, Embase, Scopus, and Web of Science were searched from database inception to November 20, 2024 in accordance with PRISMA guidelines.
    Summary · context
    22 studies meeting inclusion criteria comprised of pharmacovigilance (n = 10) and cohort studies (n = 12) were identified.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:06 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.